The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans.

ABSTRACT: The deficiently designed and conducted initial clinical development plan and the occurrence of thrombotic thrombocytopenia cases, have marked the first 12-month journey of the AstraZeneca coronavirus disease 2019 (COVID-19) vaccine after it was first administered to humans. When it was authorized, there were no available efficacy data in the elderly. However, this age group was included in the product labelling based on immunogenicity data. The lack of safety and efficacy data in the elderly that was acknowledged in the product information, triggered most European Union (EU) countries to limit the administration of this vaccine to certain age groups. In February-March/2021, after the results of observational studies supported the vaccine effectiveness in the elderly, several countries broa

SUBMITTER: Dal-Re R 

PROVIDER: S-EPMC9277994 | biostudies-literature | 2023 May-Jun

REPOSITORIES: biostudies-literature